scholarly journals Androgen Receptor Expression in Triple-Negative Breast Cancer

2019 ◽  
pp. 90-94
Author(s):  
Samane Jam ◽  
Alireza Abdollahi ◽  
Sanaz Zand ◽  
Zahra Khazaeipour ◽  
Ramesh Omranipour ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Lymphovascular Invasion ◽  
Triple Negative ◽  
Tumor Grade ◽  
Receptor Expression ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Cross Sectional

Background: Triple-negative breast cancer (TNBC) accounts for 15 to 20% of all breast cancers. These patients do not benefit from hormone therapy and other targeted treatments of breast cancer. Recently, researchers proposed the use of androgen receptor (AR)-targeted therapies in this subset of patients. The rate of AR expression in TNBC patients varies from 0 to 53%. AR positivity is associated with a better outcome for breast cancer patients. The purpose of this study was to evaluate AR status in TNBC patients and its association with other demographic and pathologic features.Methods: This cross-sectional study was conducted in the Cancer Institute of Iran, affiliated with Tehran University of Medical Sciences, in 2015. Archived formalin-fixed, paraffin-embedded breast tumor blocks were evaluated to determine the AR status of the tumors. Demographic and pathologic characteristics of the patients were retrieved from the department of pathology database. Data were analyzed with SPSS 18.0.Results: Seventy-seven TNBC patients with the mean age of 45.3 ± 11.5 were assessed. Twenty-six patients (34%) showed AR expression, and 51 patients (56%) did not have AR expression. There was no significant correlation between AR status and age, tumor size, histopathologic type of tumor, or lymph node involvement. However, AR positivity had a statistically significant association with a lower tumor grade and lymphovascular invasion (P = 0.029 and P = 0.01, respectively).Conclusion: TNBC patients with AR expression tend to have lower tumor grades and higher rates of lymphovascular invasion.

scholarly journals THE VALUE OF ANDROGEN RECEPTOR EXPRESSION IN TRIPLE NEGATIVE BREAST CANCER PATIENTS

2020 ◽  
Vol 13 (5) ◽  
pp. 35-39
Author(s):  
NATALIA YU. SHAGINA ◽  
◽  
SVETLANA B. POLIKARPOVA ◽  
IGOR K. VOROTNIKOV ◽  
VLADISLAV YU. KIRSANOV ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Receptor Expression ◽  
Androgen Receptor Expression ◽  
Breast Cancer Patients

scholarly journals Androgen Receptors Expression in Patients With Triple-negative Breast Cancer. Bivariate Correlation and Prevalence Study.

2021 ◽  
Author(s):  
Sandra Zynzya Enríquez-Brena ◽  
Lázaro Ramírez-Balderrama ◽  
Yunuén Ibiza García-Mendoza ◽  
Saulo Mendoza-Ramírez ◽  
Martha Alicia Hernández-González ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Androgen Receptors ◽  
Malignant Tumors ◽  
Receptor Expression ◽  
Inclusion Criteria ◽  
Cross Sectional ◽  
Bivariate Correlation

Abstract BACKGROUND. Breast cancer is a pathology with repercussions on public health, which is histologically classified into 2 large groups, ductal and lobular; Although there is no variability in the treatment therapy based on these characteristics, with the help of special immunohistochemical techniques it is subclassified according to the molecular classification recognized by the WHO into 5 categories, including triple-negative breast cancer, which presents a worse prognosis than that of the rest of the groups. Some of these groups are those with low expression of claudins, and others with apocrine differentiation that may have reactivity to Her2/neu or be properly triple negative. In these, adjuvant therapy is only with chemotherapy. In the subgroup of apocrine type tumors, when studying androgen receptors it was noted that they have an important role in tumorigenesis and that there may be an expression in part of triple-negative tumors, creating a therapeutic target that can benefit these patients, with benefit in clinical trials that have been conducted.METHODS. This study is an ambilective, descriptive, cross-sectional study that includes paraffin embedded tissue samples in triple-negative breast malignant tumors of patients detected in in the database of the Department of Surgical Pathology of High Specialty Medical Unit No. 1 Bajío who meet inclusion criteria. Immunohistochemistry technique was performed by manual method in three steps, using monoclonal antibody against androgen receptors (androgen receptor, Zeta Diagnostic brand, EP120 clone), and evaluated by peer review made on a Leica DM1000 light microscope. The histological variables were reviewed and the positivity or negativity of androgen receptors and their percentage of expression were assessed, replicating the H-Score system. Also, the correlation of androgen receptor expression with histological variables was performed. RESULTS. Of 76 cases that met the inclusion criteria, 18.42% had androgen receptors by immunohistochemistry. This means that about 2 out of every 10 patients with triple-negative breast cancer have tumors with presence of androgen receptors; In the cases that presented them, a search was carried out for correlations between the morphological histological variables and concerning the presence of these receptors, without finding significant associations and we corroborated that their presence is independent of the morphology, as previously described in the literature.CONCLUSIONS. In triple-negative cases, the existence or not of androgen receptors can be added to suggest offering target treatment, blocking them. Our results propose that the systematization in the search for androgen receptors in triple-negative breast cancer offers the possibility of targeted therapy. Equally important is having been able to corroborate that the presence of androgen receptors is an independent parameter to tumor histological types.

scholarly journals Regression of Triple-Negative Breast Cancer in a Patient-Derived Xenograft Mouse Model by Monoclonal Antibodies against IL-12 p40 Monomer

Cells ◽  
2022 ◽  
Vol 11 (2) ◽  
pp. 259
Author(s):  
Madhuchhanda Kundu ◽  
Sumita Raha ◽  
Avik Roy ◽  
Kalipada Pahan
Keyword(s):  
Breast Cancer ◽  
Mouse Model ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Transforming Growth Factor ◽  
Healthy Controls ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Patient Derived Xenograft

Although some therapies are available for regular breast cancers, there are very few options for triple-negative breast cancer (TNBC). Here, we demonstrated that serum level of IL-12p40 monomer (p40) was much higher in breast cancer patients than healthy controls. On the other hand, levels of IL-12, IL-23 and p40 homodimer (p402) were lower in serum of breast cancer patients as compared to healthy controls. Similarly, human TNBC cells produced greater level of p40 than p402. The level of p40 was also larger than p402 in serum of a patient-derived xenograft (PDX) mouse model. Accordingly, neutralization of p40 by p40 mAb induced death of human TNBC cells and tumor shrinkage in PDX mice. While investigating the mechanism, we found that neutralization of p40 led to upregulation of human CD4+IFNγ+ and CD8+IFNγ+ T cell populations, thereby increasing the level of human IFNγ and decreasing the level of human IL-10 in PDX mice. Finally, we demonstrated the infiltration of human cytotoxic T cells, switching of tumor-associated macrophage M2 (TAM2) to TAM1 and suppression of transforming growth factor β (TGFβ) in tumor tissues of p40 mAb-treated PDX mice. Our studies identify a possible new immunotherapy for TNBC in which p40 mAb inhibits tumor growth in PDX mice.

scholarly journals Androgen receptor expression in triple negative breast cancer and its relationship to prognostic factors

2017 ◽  
Vol 27 (3) ◽  
pp. 199-205
Author(s):  
Maximiliano Cassilha Kneubil ◽  
◽  
Alessandra Eifler Guerra Godoy ◽  
Guilherme Portela Coelho ◽  
Rafael Grochot ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Receptor Expression ◽  
Androgen Receptor Expression

Abstract P3-04-07: Androgen receptor expression in triple negative breast cancer

2015 ◽  
Author(s):  
Hannah Gilmore ◽  
Vinay Varadan ◽  
Nicole Williams ◽  
Cheryl L Thompson ◽  
Stephanie Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Receptor Expression ◽  
Androgen Receptor Expression
Sign in / Sign up

Export Citation Format

Share Document